Uncomfortable questions advanced therapies must confront as they mature

In this column, Ry Leahy asks and discusses the hard-hitting questions that the cell and gene therapy field should be addressing as it continues to evolve from a phase of pure innovation to frontline, conventional care for patients with unmet medical needs. Cell and gene therapy. Regenerative medicine. Advanced therapies. These are no longer emerging fields, seemingly sprung from science fiction. They’re funded. They’re regulated. They’re publicly traded. They are reimbursed in some major world markets. They have delivered real clinical breakthroughs. Yet still, they often behave like fields in their adolescence.   Maturing fields are forced to ask hard questions. Not...